Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old

Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial

(2013) C. Falandry et al.   EUROPEAN JOURNAL OF CANCER

Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70years)

(2013) Umberto Basso et al.   Journal of Geriatric Oncology

Age and gender effects on DNA strand break repair in peripheral blood mononuclear cells

(2012) Christian Garm et al.   AGING CELL

Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review

(2012) Marije E Hamaker et al.   LANCET ONCOLOGY

Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO

(2012) Alexandre Sostelly et al.   Journal of Geriatric Oncology

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

(2011) Ninh M. La-Beck et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx™/Doxil® in patients with hematological tumors

(2011) H. Richly et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

(2010) Jens Huober et al.   BMC CANCER

Factors that may impact on immunosenescence: an appraisal

(2010) Joseph Ongrádi et al.   Immunity & Ageing

Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer

(2008) Alessandro M Minisini et al.   Expert Review of Anticancer Therapy